ReviewJournal of neuro-oncology1999
Glucocorticoid treatment of primary CNS lymphoma.
Review in Journal of neuro-oncology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.
- Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.Haematologica · 2017Guideline
- Incidence of Underlying Abnormal Findings on Routine Magnetic Resonance Imaging for Bell Palsy.JAMA network open · 2023Trial
- Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort.Neuro-oncology · 2010Trial
- MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma.Cancer research communications · 2026Article
- Prebiopsy Steroids and Diagnostic Yield in Patients With Diffuse Large B-Cell Lymphoma.JAMA network open · 2025Article
- Glioblastoma with markedly reduced contrast enhancement after corticosteroid administration: Increased density and reduced diffusion capability are noteworthy.Radiology case reports · 2025Article
- Histopathological Diagnosis of Primary Central Nervous System Lymphoma after Therapy with Corticosteroids or Anticoagulants.Cancers · 2024Article
- Clinical and Genomic Profile of Primary Cranial Neurolymphomatosis.Journal of blood medicine · 2024Article
- Mesoporous Materials as Elements of Modern Drug Delivery Systems for Anti-Inflammatory Agents: A Review of Recent Achievements.Pharmaceutics · 2022Review
- Motor deficits at presentation and predictors of overall survival in central nervous system lymphomas.Journal of neuro-oncology · 2021Article
- Article
- Facial nerve paralysis caused by a T-cell lymphoma.Clinical case reports · 2020Article
- Dexamethasone Interferes with Autophagy and Affects Cell Survival in Irradiated Malignant Glioma Cells.Journal of Korean Neurosurgical Society · 2020Article
- Recent advances in the management of primary central nervous system lymphoma.Blood research · 2020Review
- Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.Journal of neuro-oncology · 2020Article
- Primary Central Nervous System Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis: Case Report and Review of Literature.NMC case report journal · 2020Article
- Diagnosis of primary central nervous system lymphoma: a systematic review of the utility of CSF screening and the role of early brain biopsy.Neuro-oncology practice · 2019Review
- Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.Neuro-oncology · 2019Review
- Recurrent Epstein-Barr Virus-positive (EBV+) Primary Central Nervous System Lymphoma (PCNSL) in a Patient with Clinical Features of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS).Internal medicine (Tokyo, Japan) · 2019Article
- Diagnosis and Treatment of Primary Central Nervous System Angiitis.Current treatment options in neurology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid therapy may result in the rapid resolution of cerebral mass lesions in patients with primary CNS lymphoma. Since glucocorticoids will obscure the histological diagnosis of primary CNS lymphoma upon biopsy, steroids should be withheld if primary CNS lymphoma is a likely diagnosis by neuroradiological criteria. The lympholytic effect of glucocorticoids is mediated by cytoplasmic steroid receptors which are translocated to the nucleus and signal apoptosis. Glucocorticoid-induced apoptosis of lymphoid cells does not require wild-type p53 activity, seems not to depend on caspase activation, but is attenuated by the bcl-2 protooncogene product. Longterm glucocorticoid therapy of primary CNS lymphoma is not recommended because relapse is probably inevitable and because of the prominent side effects of long-term glucocorticoid treatment. Further, long-term glucocorticoid treatment is contraindicated in immunocompromised patients with primary CNS lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.